AER enters May with a notable split in signals: the CEO booked a $22 million sale at the peak of the stock's recent range, yet options traders have swung sharply toward calls — the most bullish lean of the past year.
The insider activity is the headline item this week. On April 20, CEO Aengus Kelly sold 152,010 shares at $147.45, pocketing $22.4 million. The CFO and General Counsel also sold on the same day, with the CFO clearing $1.74 million and General Counsel $870,000. All three received equity awards simultaneously, suggesting these were planned award-linked disposals rather than a discretionary exit. Still, the collective selling came right at what proved to be the week's high — AER closed Wednesday at $138.11, down about 6% from the April 20 sale price. Kelly retains over 6.7 million shares, or roughly 4.1% of the company, so his alignment with shareholders remains substantial. On a 90-day net basis, insiders are marginally positive in share count terms, though negative on cash given the size of the Kelly sale.
Options positioning tells a more constructive story. The put/call ratio dropped to 0.49 on Wednesday — nearly 1.8 standard deviations below its 20-day average of 0.64. That is the lowest (most call-heavy) reading in the past year, with the 52-week low at 0.23 and the high at 0.83. The move represents a decisive rotation toward calls over the past two weeks: through mid-April the PCR was consistently running above 0.70. Something changed around April 21, and that change has been sustained. Options traders are not positioned defensively here.
Short positioning is modest and not the story. Short interest amounts to 1.15% of the free float — roughly 1.9 million shares. It fell about 1.4% over the week and, after a brief spike through mid-April that pushed it just above 2 million shares, has been unwinding. Borrowing is trivially easy: cost to borrow dropped to 0.16%, two-thirds below where it was a week ago, and availability in the lending market is extremely loose. There is no meaningful squeeze setup and no evidence of aggressive directional short positioning. The ORTEX short score of 28.9 sits well below mid-range, consistent with light and retreating short interest.
The Street is constructive and recently active. Truist Securities raised its target to $161 from $159 this morning, maintaining a Buy. Morgan Stanley nudged its Equal-Weight target to $160 from $150 in early March. Both moves arrive after a period of broad target creep — Barclays, B of A, Susquehanna, and TD Cowen all raised targets between October and January, with most now clustered in the $150–$162 range. The consensus mean target is $163.78, implying about 17% upside from the current $138.11 price. The stock's P/E is near 8.7x and P/B sits at 1.1x — undemanding for a company generating over $8.4 billion in revenue and $5.4 billion in operating cash flow. The EV/EBITDA of 8.6x has been drifting lower over the past 30 days, quietly compressing the multiple even as the price held near flat on the week (-0.1%).
Institutional ownership is deep and stable. BlackRock holds 7.7% and added shares in Q1. State Street and T. Rowe Price both added modestly in the latest quarter. Mawer Investment and UBS Asset Management both made sizeable additions in Q4. The register looks well-anchored, and the absence of any large institutional exit leaves the Kelly sale as the dominant insider signal.
Q1 2026 earnings were released on April 29. The next scheduled event is July 29. With the print now in the rearview and options traders notably more bullish than a fortnight ago, the weeks ahead will test whether the call-heavy positioning was correct — or whether the insider selling at $147 turns out to have been better-timed than it appeared at the time.
See the live data behind this article on ORTEX.
Open AER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
